REGENXBIO Inc. Files 2025 Proxy Statement
Ticker: RGNX · Form: DEF 14A · Filed: Apr 8, 2025 · CIK: 1590877
Sentiment: neutral
Topics: proxy-statement, executive-compensation, corporate-governance
TL;DR
REGENXBIO proxy filing out - check exec pay & vote on company matters.
AI Summary
REGENXBIO Inc. filed a DEF 14A on April 8, 2025, for the fiscal year ending December 31, 2025. The filing details executive compensation and other corporate governance matters. Key individuals mentioned in relation to compensation include Kenneth T. Mills and Curran Simpson.
Why It Matters
This filing provides shareholders with crucial information regarding executive compensation, director nominations, and other voting matters, enabling informed participation in the company's governance.
Risk Assessment
Risk Level: low — This is a routine DEF 14A filing detailing executive compensation and corporate governance, not indicating immediate financial distress or significant operational changes.
Key Numbers
- 20250408 — Filing Date (Date the DEF 14A was filed with the SEC.)
- 20250530 — Period of Report (The period the filing pertains to.)
- 1231 — Fiscal Year End (Indicates the end of the company's fiscal year.)
Key Players & Entities
- REGENXBIO Inc. (company) — Filer of the DEF 14A
- Kenneth T. Mills (person) — Member related to compensation and equity awards
- Curran Simpson (person) — Member related to compensation
FAQ
What is the primary purpose of a DEF 14A filing?
A DEF 14A filing, also known as a Proxy Statement, is used to solicit shareholder votes on important corporate matters, such as the election of directors, executive compensation, and other proposals.
Who are the key individuals mentioned in relation to executive compensation in this filing?
Kenneth T. Mills and Curran Simpson are mentioned in relation to executive compensation and equity awards for various fiscal years.
When is REGENXBIO Inc.'s fiscal year end?
REGENXBIO Inc.'s fiscal year ends on December 31st.
What is the SEC file number for REGENXBIO Inc.'s filing?
The SEC file number for REGENXBIO Inc.'s DEF 14A filing is 001-37553.
What industry does REGENXBIO Inc. operate in?
REGENXBIO Inc. operates in the Biological Products (No Diagnostic Substances) industry, with SIC code 2836.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 8, 2025 by Kenneth T. Mills regarding REGENXBIO Inc. (RGNX).